{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:31:24Z","timestamp":1787020284477,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"New York State CAT"},{"DOI":"10.13039\/100007066","name":"New York City Economic Development Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deerfield Management","award":["X-Seed Award"],"award-info":[{"award-number":["X-Seed Award"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15435-8","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T01:57:34Z","timestamp":1765331854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy"],"prefix":"10.1186","volume":"26","author":[{"given":"Queenie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigme P.","family":"Dorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandali G.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petvy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fizza","family":"Aijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda C.","family":"Ihuoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidiebere U.","family":"Awah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"15435_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","volume":"130","author":"KA Lowe","year":"2013","unstructured":"Lowe KA, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130:107\u201314.","journal-title":"Gynecol Oncol"},{"key":"15435_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.601512","volume":"11","author":"M Jeyshka","year":"2021","unstructured":"Jeyshka M, Reyes-Gonzalez PE. Vivas Meija. c-MYC and epithelial ovarian cancer. Front Oncol. 2021;11:601512.","journal-title":"Front Oncol"},{"key":"15435_CR3","doi-asserted-by":"publisher","unstructured":"Tan A, Ince et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun.\u00a02015;6:7419. https:\/\/doi.org\/10.1038\/ncomms8419.","DOI":"10.1038\/ncomms8419"},{"key":"15435_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0002-9378(89)90750-3","volume":"161","author":"DM Smith","year":"1989","unstructured":"Smith DM, Groff DE, Pokul RK, Bear JL, Delgado G. Determination of cellular oncogene rearrangement or amplification in ovarian adenocarcinomas. Am J Obstet Gynecol. 1989;161:911\u20135. https:\/\/doi.org\/10.1016\/0002-9378(89)90750-3.","journal-title":"Am J Obstet Gynecol"},{"key":"15435_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419\u201325.","journal-title":"J Clin Oncol"},{"key":"15435_CR6","first-page":"1320","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. CancerSpectrum Knowledge Environment. 2003;95:1320\u20139.","journal-title":"CancerSpectrum Knowledge Environment"},{"key":"15435_CR7","unstructured":"National Cancer Institute. Cancer stat facts: ovarian cancer. 2024. Accessed at https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html on 17 Jan 2025."},{"key":"15435_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1247\/csf.12.121","volume":"12","author":"H Yasue","year":"1987","unstructured":"Yasue H, Takeda A, Ishibashi M. Amplification of the c-myc gene and the elevation of its transcripts in human ovarian tumor lines. Cell Struct Funct. 1987;12:121\u20135. https:\/\/doi.org\/10.1247\/csf.12.121.","journal-title":"Cell Struct Funct"},{"key":"15435_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0046-8177(90)90199-F","volume":"21","author":"H Sasano","year":"1990","unstructured":"Sasano H, Garrett CT, Wilkinson DS, Silverberg S, Comerford J, Hyde J. Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum Pathol. 1990;21:382\u201391. https:\/\/doi.org\/10.1016\/0046-8177(90)90199-F.","journal-title":"Hum Pathol"},{"key":"15435_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/0090-8258(90)90069-W","volume":"38","author":"VV Baker","year":"1990","unstructured":"Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol. 1990;38:340\u20132. https:\/\/doi.org\/10.1016\/0090-8258(90)90069-W.","journal-title":"Gynecol Oncol"},{"key":"15435_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/0046-8177(92)90125-M","volume":"23","author":"H Sasano","year":"1992","unstructured":"Sasano H, Nagura H, Silverberg SG. Immunolocalization of c-myc oncoprotein in mucinous and serous adenocarcinomas of the ovary. Hum Pathol. 1992;23:491\u20135. https:\/\/doi.org\/10.1016\/0046-8177(92)90125-M.","journal-title":"Hum Pathol"},{"issue":"4","key":"15435_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/0008-5472.CAN-20-3173","volume":"81","author":"Daniele Chaves-Moreira","year":"2021","unstructured":"Chaves-Moreira Daniele, et al. Unraveling the Mysteries of PAX8 in reproductive tract cancers. Cancer Res. 2021;81(4):806\u201310.","journal-title":"Cancer Res"},{"issue":"15","key":"15435_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152663","volume":"16","author":"CU Awah","year":"2024","unstructured":"Awah CU, Mun JS, Paragodaarachchi A, Boylu B, Ochu C, Matsui H, et al. The engineered drug 3\u2032UTRMYC1-18 degrades the c-MYC-STAT5A\/B-PD-L1 complex in vivo to inhibit metastatic triple-negative breast cancer. Cancers. 2024;16(15):2663.","journal-title":"Cancers"},{"key":"15435_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41420-022-01072-8","volume":"8","author":"P Qiu","year":"2023","unstructured":"Qiu P, Jie Y, et al. Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5. Cell Death Discov. 2023;8:276.","journal-title":"Cell Death Discov"},{"issue":"12_Supplement","key":"15435_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-1809","volume":"82","author":"CU Awah","year":"2022","unstructured":"Awah CU, Dong F, Glemaud Y, Levine F, Weiser D, Ogunwobi O. Engineered destabilized ARE on the 3UTR of MYC degrades oncogenic c-MYC transcript and protein and induces apoptosis in multiple cancer type. Cancer Res. 2022;82(12_Supplement):1809. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-1809.","journal-title":"Cancer Res"},{"key":"15435_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2013.12.026","volume":"13","author":"JV Geisberg","year":"2014","unstructured":"Geisberg JV, Moqtaderi Z. Global analysis of mRNA isoform half-lives reveals stabilizing and destabilizing elements in yeast. Cell. 2014;13:812\u201324.","journal-title":"Cell"},{"key":"15435_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrm4063","volume":"16","author":"SL Andersen","year":"2015","unstructured":"Andersen SL, Jensen TH. Nonsense mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16:665\u201377.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"15435_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrg3160","volume":"13","author":"DR Schonenberg","year":"2012","unstructured":"Schonenberg DR, Maquat LE. Regulation of cytoplasmic mRNA decay. Nat Rev Genet. 2012;13:246\u201359.","journal-title":"Nat Rev Genet"},{"key":"15435_CR19","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1021\/acs.nanolett.6b02577","volume":"16","author":"S Rampersaud","year":"2016","unstructured":"Rampersaud S, Fang J, et al. The effect of cage shape on nanoparticle-based drug carriers: anticancer drug release and efficacy via receptor blockade using dextran-coated iron oxide nanocages. Nano Lett. 2016;16:7357\u201363.","journal-title":"Nano Lett"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15435-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:55:44Z","timestamp":1768366544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15435-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15435"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15435-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with relevant guidelines and regulations. We obtained IACUC approved for the animal studies. All methods are reported in accordance with ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CUA has filed patents based on these findings. HM and CUA have filed patents on nanocage delivery systems. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}